The Food and Drug Administration (FDA) did not act to stop off-label prescribing for fast-acting fentanyl drugs, putting patients at high risk of accidental overdose and death, The New York Times reports.
The drugs are approved only for cancer patients with high opioid tolerance. They have been prescribed off-label, meaning for other purposes, to patients with back pain and migraines, the article notes. The drugs are quick-absorbing fentanyl sprays, tablets and lozenges that contain a narcotic up to 50 times stronger than heroin, and up to 100 times stronger than morphine. These drugs include Actiq, Fentora and Subsys.
Full story at drugfree.org
Substance Abuse Confidentiality Regulations
This CEU course is intended to ensure that a patient receiving treatment for a substance use disorder (SUD) in a Part 2 program, Title 42 of the Code of Federal Regulations (CFR) Confidentiality of Substance Use Disorder Patient Records, does not face adverse consequences in relation to issues such as criminal proceedings and domestic proceedings such as those related to child custody, divorce, or employment. Part 2 protects the confidentiality of SUD patient records by restricting the circumstances under which Part 2 Programs or other lawful holders can disclose such records.
After a Suicide: A Toolkit for Schools
The suicide of a student can leave a school faced with grieving students, distressed parents and school staff, media attention, and a community struggling to understand what happened and why. This CE course provides guidance and tools for activities that help people cope with the emotional distress resulting from a suicide and prevent additional trauma that could lead to further suicidal behavior and deaths.